Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy

1 Guidance

2 The technology

3 The manufacturer's submission

4 Consideration of the evidence

5 Implementation

6 Recommendations for further research

7 Related NICE guidance

8 Review of guidance

Appendix A: Appraisal Committee members and NICE project team

Appendix B: Sources of evidence considered by the Committee

Changes after publication

About this guidance

Select chapters and save as Word or PDF documents to print or share